怀孕期间发生性结肠炎的病例,以及在接受生物疗法时晚年分娩的病例
Tomotaka Tanaka1, Daiki Hirano1, Syohei Ishimaru1
1Department of Gastroenterology, Tsuchiya General Hospital, Hiroshima, JPN.
Cureus
|September 12, 2024
概括
对于性结肠炎患者来说,在怀孕期间使用infliximab和ustekinumab等生物疗法似乎是安全的. 这项案例研究表明,在两次怀孕中成功管理和缓解疾病,缓解了对孕妇生物使用的担忧.
科学领域:
- 胃肠道学和免疫学
- 生殖医学 生殖医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 生物疗法越来越多地用于炎症性肠道疾病,如性结肠炎 (UC).
- 怀孕期间这些先进治疗方法的安全性和有效性存在重大不确定性.
- 保持疾病缓解对于母亲和胎儿的健康至关重要.
研究的目的:
- 在怀孕期间使用生物药物成功治疗长期性结肠炎的案例.
- 评估Infliximab和Ustekinumab在维持性结肠炎缓解的安全性和有效性,在两个怀孕期间.
- 为在孕妇患有炎症性肠病患者中使用生物治疗的有限文献做出贡献.
主要方法:
- 一个46岁的女性病例报告,她30年来一直患有性结肠炎.
- 在两个不同的怀孕期间,用因弗利克西马布和乌斯特基努马布进行疾病过程和治疗的记录.
- 关于在怀孕期间治疗炎症性肠病的生物治疗安全性的现有文献的综述.
主要成果:
- 患者在两次怀孕期间都保持了性结肠炎的临床缓解,没有恶化.
- 在母亲或新生儿身上没有报告与infliximab或ustekinumab相关的不良事件.
- 生物疗法有效控制疾病活动,支持其在这种情况下的使用.
结论:
- 这一案例表明,infliximab和ustekinumab可以安全有效地用于在怀孕期间保持性结肠炎缓解.
- 在这种情况下,成功的结果提供了有价值的证据,支持在孕妇IBD患者中使用生物剂.
- 需要进一步的研究和案例研究来巩固对怀孕中的生物安全性的理解.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
153
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
153
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:29Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98